The role of paraoxonase (PON1) is the detoxication of organophosphates and its human polymorphism

被引:133
|
作者
Costa, LG
Li, WF
Richter, RJ
Shih, DM
Lusis, A
Furlong, CE
机构
[1] Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA
[2] Univ Washington, Dept Med, Seattle, WA USA
[3] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
关键词
paraoxonase; PON1; chlorpyrifos; parathion; diazinon; soman; sarin;
D O I
10.1016/S0009-2797(99)00055-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In human populations, serum paraoxonase (PON1) exhibits a substrate dependent polymorphism. The Arg,,, isoform hydrolyzes paraoxon rapidly but diazoxon, soman and especially sarin slowly. On the other hand, the Gin(192) isoform hydrolyzes paraoxon slowly, but diazoxon, soman and sarin more rapidly than the Arg(192) isoform. Our experiments with a mouse model system have convincingly shown that PON1 plays a major role in the detoxication of organophosphate (OP) compounds processed through the P450/PON1 pathway. Recent studies have also shown that PON1 plays an important role in the metabolism of oxidized lipid compounds, Currently, there is an effort underway to identify genes and polymorphisms that play an important role in 'environmental susceptibility'. The PON1 polymorphism has been cited as a prime example of such a genetic polymorphism. The advent of the polymerase chain reaction (PCR) for DNA amplification with improvements, modifications and automation has provided a very convenient way to do individual genotyping. It is tempting to set up large scale PCR analyses of populations to determine individuals at risk for environmental exposures affected by the PON1 polymorphism. In fact, a number of such studies have already been carried out in examining the relationship of the PON1 polymorphism to vascular disease. We advocate the use of a high throughput two-dimensional enzyme assay that provides both PON1 genotype and phenotype (PON1 status). The high level of variation of gene expression within each genetic class in humans, together with our animal model studies indicate that it is very important to determine PON1 status as opposed to PON1 genotype alone. Experiments in rats and mice have shown that injection of PON1 purified from rabbit serum by the i.v., i.p, or i.m, route, significantly increases PON1 activities in rodents' plasma. Under these conditions, the acute toxicity (assessed by the degree of acetylcholinesterase inhibition) of paraoxon and chlorpyrifos oxon is significantly decreased, compared to control animals. Protection is maximal when PON1 is administered before the OPs, but still occurs when PON1 is utilized as a pest-exposure treatment. Furthermore, protection by PON1 is also provided toward the parent compound chlorpyrifos. Pon1-knockout mice display a much greater sensitivity to chlorpyrifos oxon toxicity than wild mice. However, the acute toxicity of guthion, which is not a substrate for PON1, does not differ between knockout and wild mice. These observations underline the importance of considering both genetic variability of enzyme isoform as well as enzyme level (PON1 status) and the developmental time course of appearance of PON1 in developing risk assessment models. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:429 / 438
页数:10
相关论文
共 50 条
  • [1] Novel Nucleophiles Enhance the Human Serum Paraoxonase 1 (PON1)-mediated Detoxication of Organophosphates
    Chambers, Janice E.
    Chambers, Howard W.
    Meek, Edward C.
    Funck, Kristen E.
    Bhavaraju, Manikanthan H.
    Gwaltney, Steven R.
    Pringle, Ronald B.
    [J]. TOXICOLOGICAL SCIENCES, 2015, 143 (01) : 46 - 53
  • [2] Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects
    Sirivarasai, Jintana
    Kaojarern, Sming
    Yoovathaworn, Krongtong
    Sura, Thanyachai
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2007, 168 (03) : 184 - 192
  • [3] A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
    Suehiro, T
    Nakamura, T
    Inoue, M
    Shiinoki, T
    Ikeda, Y
    Kumon, Y
    Shindo, M
    Tanaka, H
    Hashimoto, K
    [J]. ATHEROSCLEROSIS, 2000, 150 (02) : 295 - 298
  • [4] Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates
    Costa, LG
    Cole, TB
    Furlong, CE
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2003, 41 (01): : 37 - 45
  • [5] Rational design of paraoxonase 1 (PON1) for the efficient hydrolysis of organophosphates
    Quang Anh Tuan Le
    Chang, Rakwoo
    Kim, Yong Hwan
    [J]. CHEMICAL COMMUNICATIONS, 2015, 51 (77) : 14536 - 14539
  • [6] GENETIC POLYMORPHISM IN PARAOXONASE 1 (PON1): POPULATION DISTRIBUTION OF PON1 ACTIVITY
    Ginsberg, Gary
    Neafsey, Patricia
    Hattis, Dale
    Guyton, Kathryn Z.
    Johns, Douglas O.
    Sonawane, Babasaheb
    [J]. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 473 - 507
  • [7] The active site of human paraoxonase (PON1)
    Josse, D
    Lockridge, O
    Xie, WH
    Bartels, F
    Schopfer, LM
    Masson, P
    [J]. JOURNAL OF APPLIED TOXICOLOGY, 2001, 21 : S7 - S11
  • [8] Polymorphisms in the human paraoxonase (PON1) promoter
    Brophy, VH
    Hastings, MD
    Clendenning, JB
    Richter, RJ
    Jarvik, GP
    Furlong, CE
    [J]. PHARMACOGENETICS, 2001, 11 (01): : 77 - 84
  • [9] The PON1 gene and detoxication
    Furlong, CE
    Li, WF
    Brophy, VH
    Jarvik, GP
    Richter, RJ
    Shih, DM
    Lusis, AJ
    Costa, LG
    [J]. NEUROTOXICOLOGY, 2000, 21 (04) : 581 - 587
  • [10] Human paraoxonase (PON1) polymorphisms in Taiwanese
    Li, WF
    Chung, MC
    Chuang, HY
    Chang, LW
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 66 - 66